clinicaltrials.gov
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted RSS 源
直接获取 ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted 的最新更新，更新一发布就能看到。
最新文章
在常用阅读平台获取 ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted
问题
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted 的 RSS 订阅源网址是什么？
订阅源地址为 https://clinicaltrials.gov/api/rss?term=%28%22generalized+myasthenia+gravis%22+OR+%22myasthenia+gravis%22%29+AND+%28eculizumab+OR+ravulizumab+OR+gefurulimab+OR+inebilizumab+OR+nipocalimab+OR+zilucoplan+OR+rozanolixizumab+OR+efgartigimod+OR+remibrutinib%29&dateField=LastUpdatePostDate。将其粘贴到任意 RSS 阅读器中，或点击“立即关注”在 Feeder 中阅读。
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted 多久发布一次？
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted 的发布频率为 每周约 5 次。 最近一篇文章发布于 5 days前。
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted 的 RSS 订阅源是否正常？
是的。Feeder 于 4 minutes前检查过，订阅源响应正常。
如何在 Feeder 中关注 ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted？
点击“立即关注”；如果还没有账户，请先注册。 Feeder 免费套餐最多支持 200 个订阅源，可在网页、iPhone 和 Android 上使用。无需信用卡。
在 Feeder 中关注 ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted
Feeder 免费套餐最多支持 200 个订阅源，可在网页、iPhone 和 Android 上使用。无需信用卡。